來源: MarketWatch ↗
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
|
暫時無法翻譯，請重試。
來源報導重點
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
在 MarketWatch 閱讀原始報導 ↗